Wednesday, December 17, 2014

EyewireTV—AREDS Ocular Vitamins Study, Lucentis Designation for DR

In this week's EyewireTV, a study evaluating the top-selling ocular nutritional supplements finds that they contain the same ingredients as the AREDS and AREADS2 formulas, but not all contained the recommended doses; and the FDA grants breakthrough therapy designation for Lucentis (ranibizumab) for the treatment of diabetic retinopathy. Also, Shire provides updates on several products in its ophthalmic pipeline, including SHP607 for the prevention of retinopathy of prematurity, and lifitegrast for the treatment of dry eye disease. (1315 Views)

Watch Video

Wednesday, December 10, 2014

EyewireTV — Rhopressa Phase 3 Trial, Dropless Cataract Surgery

In this week’s EyewireTV, Aerie Pharmaceuticals completes enrollment in the 400-patient phase 3 clinical trial of glaucoma drug candidate Rhopressa; and CenterVue announces FDA 510(k) clearance for its Eidon true-color confocal scanner. In the feature, three ophthalmologists share their thoughts on providing anti-inflammatory and anti-bacterial agents during cataract surgery. (2029 Views)

Watch Video

Wednesday, December 03, 2014

EyewireTV — New Eylea Indication Review, Vitrectomy Reimbursement Cuts

In this week's EyewireTV, the FDA grants priority review for Eylea (aflibercept) for the treatment of diabetic retinopathy in patients with diabetic macular edema; and i-Optics announces the commercial launch of the Cassini Total Corneal Astigmatism functionality, which is designed to measure both anterior and posterior astigmatism. Also, the Centers for Medicare and Medicaid Services unveils reimbursement cuts for vitrectomy procedures starting in 2015. (1858 Views)

Watch Video

Tuesday, November 25, 2014

EyewireTV — Actavis and Allergan CEOs Reaction, First MillennialEYE Live

In this week's EyewireTV, days after Actavis announced it will acquire Allergan in a cash and stock deal worth $66 billion, Actavis President and CEO Brent Saunders, and Allergan Chairman and CEO David Pyott, speak with EyewireTV about the deal; and several young leaders in ophthalmology discuss the most important takeaway messages from the inaugural MillennialEYE Live, an innovative meeting hosted by Bryn Mawr Communications' digital publication, MillennialEYE, in Austin, Texas. (2898 Views)

Watch Video

Wednesday, November 19, 2014

EyewireTV —Actavis Buys Allergan, Valeant Buys Nicox, Vision for Mars Update

In this week's EyewireTV, in a blockbuster deal that will likely thwart a long and aggressive hostile takeover bid by Valeant, Actavis agrees to acquire Allergan for $66 billion in cash and stock; and Valeant acquires Nicox’s US diagnostics business, Nicox Inc., in a deal worth up to $20 million. Also, a team of researchers, NASA scientists, leading ophthalmologists, and business representatives, collectively known as the Vision for Mars team, makes several recommendations regarding various eye conditions in astronauts. (1980 Views)

Watch Video

Wednesday, November 12, 2014

EyewireTV — Allergan-Actavis Discussions, Phase 3 Dry Eye Study

In this week's EyewireTV, new reports emerge that Allergan is in talks with generic and specialty drugmaker Actavis about a possible takeover deal; and Eleven Biotherapeutics completes patient enrollment in its first phase 3 clinical study of EBI-005, its lead product candidate for dry eye disease. In the feature, three leading ophthalmologists discuss the advantages of having an integrated care model in their practice. (2389 Views)

Watch Video

Wednesday, November 05, 2014

EyewireTV — NASA Eye Health, Omidria CMS Pass-Through

In this week's EyewireTV, a new public-private partnership led by a NASA entity is formed with the task of safeguarding the eye during and after long-duration space travel; and Omeros receives transitional pass-through status from the Centers for Medicare & Medicaid Services for its lead product Omidria. Also, new research shows that the severity of AMD in one eye is associated with the incidence and progression of AMD in the other eye. (2033 Views)

Watch Video

Wednesday, October 29, 2014

EyewireTV — FDA LASIK Study, Allergan-Valeant Developments, Innovator Award

In this week’s EyewireTV, a large FDA-sponsored study evaluating the safety and effectiveness of LASIK shows high rates of patient satisfaction and a low prevalence of postoperative symptoms; Allergan reports strong third-quarter sales growth and raises its outlook, while Valeant hints that it may be raising its takeover bid. Also, Sue Washer, president and CEO of Applied Genetic Technologies, is named the recipient of the OIS@AAO Innovator Award. (2043 Views)

Watch Video

Tuesday, October 21, 2014

EyewireTV — Breaking Industry News From the AAO Meeting in Chicago

In this week's EyewireTV, releases preliminary data from its National Institutes of Health-sponsored Protocol T study, which examined the efficacy and safety of three anti-VEGF agents in patients with diabetic macular edema; and Abbott Medical Optics and Carl Zeiss Meditec enter a nonexclusive commercial collaboration in which AMO will sell and distribute Zeiss’ cataract surgery portfolio in the United States. Also, Carl Zeiss Meditec introduces its Cataract Suite Markerless range of products to the US market. (3886 Views)

Watch Video

Wednesday, October 15, 2014

EyewireTV — Lucentis Priority Review, Implantable Miniature Telescope, Eyewire Redesign

In this week's EyewireTV, the FDA grants priority review to Genentech’s biologics license application for Lucentis (ranibizumab) the treatment of diabetic retinopathy; and the FDA approves VisionCare Ophthalmic Technologies' Implantable Miniature Telescope for use in patients with bilateral end-stage AMD who are 65 or older. Also, EyewireTV News Director Stephen Daily provides details of the redesign of (2144 Views)

Watch Video

Wednesday, October 08, 2014

EyewireTV — New Eylea Indication, Second Sight AMD Study, Loteprednol Etabonate Study

In this week's EyewireTV, the FDA approves Regeneron’s Eylea (aflibercept) for the treatment of macular edema following retinal vein occlusion; and Second Sight Medical Products announces that its dry AMD feasibility study, the first study of retinal implants in patients with AMD, will begin in November. In the feature, we ask leading ophthalmologists and a practice administrator to share their thoughts on the potential to grow their practice through premium and elective services. (1754 Views)

Watch Video

Wednesday, October 01, 2014

EyewireTV — Ozurdex Expanded Indication, Iluvien FDA Approval, Avedro CXL Resubmission

In this week’s EyewireTV, the FDA approves an expanded indication for Allergan’s Ozurdex (dexamethasone intravitreal implant 0.7 mg) for the treatment of diabetic macular edema; and Alimera Sciences’ Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) receives FDA approval for the treatment of DME in patients who were previously treated with corticosteroids and did not have a clinically significant rise in IOP. Also, Avedro resubmits a new drug application to the FDA for its riboflavin ophthalmic solution and KXL System. (2449 Views)

Watch Video
Load More